UTILITY PATENT APPLICATION TRANSMITTAL (Small Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. 124169-1010 (OTA 02-036)

Total Pages in this Submission 163

TO THE ASSISTANT COMMISSIONER FOR PATENTS

B x Patent Application Washington, D.C. 20231	
Transmitted herewith for filing under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new utilit invention entitled:	y patent application for an
Anti-Infective Endotracheal Tube	519 519
and invented by: Rabih O. Darouiche Randall A. Prince	10/664 10/664
If a CONTINUATION APPLICATION, check appropriate box and supply the requisite info	
☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior applica	
Which is a: Continuation Divisional Continuation-in-part (CIP) of prior application which is a:	ition No.:
☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior applica	ition No.:
Enclosed are: Application Elements	
Filing fee as calculated and transmitted as described below	
2. Specification having pages and including the follo	wing:
a. 🗵 Descriptive Title of the Invention	
b. 🗵 Cross References to Related Applications (if applicable)	
c. Statement Regarding Federally-sponsored Research/Development (if applications)	plicable)
d. Reference to Sequence Listing, a Table, or a Computer Program Listing	Appendix
e. 🗵 Background of the Invention	
f. 🗵 Brief Summary of the Invention	
g. 🗵 Brief Description of the Drawings (if filed)	
h. 🗵 Detailed Description	
i. 🗷 Claim(s) as Classified Below	
j. 🗵 Abstract of the Disclosure	

UTILITY PATENT APPLICATION TRANSMITTAL (Small Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. 124169-1010 (OTA 02-036)

Total Pages in this Submission 163

3. \(\subseteq \text{ Drawing(s) (when necessary as prescribed by 35 USC 113)} a. 🛛 Formal **Number of Sheets** b. 🗀 Informal Number of Sheets □ Oath or Declaration

b. 🔲	Copy from a prior applicat	tion (3	7 CFR 1.63(d)) (for continuation/divisional application only)
с. 🗆	With Power of Attorney		Without Power of Attorney

Application Elements (Continued)

d. DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. 1.63(d)(2) and 1.33(b).

The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby

Unexecuted

	incorporated by reference therein.
6.	CD ROM or CD-R in duplicate, large table or Computer Program (Appendix)

- Application Data Sheet (See 37 CFR 1.76) 7. ☐ Nucleotide and/or Amino Acid Sequence Submission (if applicable, all must be included)
 - a.

 Computer Readable Form (CFR) i.

 CD-ROM or CD-R (2 copies); or ii. 🔲

Paper

a. Newly executed (original or copy)

c.

Statement(s) Verifying Identical Paper and Computer Readable Copy

Accompanying Application Parts

9.	ш	Assignment Papers (cover sneet & document(s))
0.		37 CFR 3.73(B) Statement (when there is an assignee)
1.		English Translation Document (if applicable)
2	X	Information Disclosure Statement/PTO-1449 X Conies of IDS Cit

- Information Disclosure Statement/PTO-1449
- 13. ☐ Preliminary Amendment
- Return Receipt Postcard (MPEP 503) (Should be specifically itemized)
- 16.

 Certificate of Mailing

	First Class	X	Express Mail (Specify Label No.):	EV 322136414 US
--	-------------	---	-----------------------------------	-----------------

UTILITY PATENT APPLICATION TRANSMITTAL (Small Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. 124169-1010 (OTA 02-036)

Total Pages in this Submission 163

		Accompanying Application Parts (Continued)
17.	×	Applicant claims small entity status. See 37 CFR 1.27.
		☐ (Optional) Small Entity Statement(s) - Specify Number of Statements Submitted:
18.		Additional Enclosures (please identify below):
		Request That Application Not Be Published Pursuant To 35 U.S.C. 122(b)(2)
19.		Pursuant to 35 U.S.C. 122(b)(2), Applicant hereby requests that this patent application not be published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in this application has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication of applications 18 months after filing of the application.
		Warning
		An applicant who makes a request not to publish, but who subsequently files in a foreign country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), must notify the Director of such filing not later than 45 days after the date of the filing of such foreign or international application. A failure of the applicant to provide such notice within the prescribed period shall result in the application being regarded as abandoned, unless it is shown to the satisfaction of the Director that the delay in submitting the notice was unintentional.

UTILITY PATENT APPLICATION TRANSMITTAL (Small Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. 124169-1010 (OTA 02-036)

Total Pages in this Submission 163

Fee Calculation and Transmittal

CLAIMS AS FILED							
For	#Filed	#Allowed	#Extra		Rate		Fee
Total Claims	13	- 20 =	0	x	\$9.00		\$0.00
ndep. Claims	3	- 3 =	0	x	\$42.00		\$0.00
/lultiple Dependen	t Claims (check	if applicable)					\$0.00
						BASIC FEE	\$375.00
OTHER FEE (spec	cify purpose)						\$0.00
					TOTA	L FILING FEE	\$375.00
as described be	ner is hereby au	thorized to charg copy of this she		eposit Acc		. 07-0153	

Dated: September 17, 2003

09/43/2003 HGUTEMA1 00000005 10664519

01 FC:2001

375.00 OP

pursuant to 37 C.F.R. 1.311(b).

☑ Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17.

☐ Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance,

Tim Headley Reg. No. 31,765

Gardere Wynne Sewell LLP 1000 Louisiana, Suite 3400 Houston, Texas 77002-5007

Phone: 713 276 5320 Fax: 713 276 6320

theadley@gardere.com

cc: Patrick Turley

Baylor College of Medicine